Liminatus Pharma amends InnocsAI merger terms to use non-voting convertible preferred stock

• Liminatus Pharma reworked its merger with InnocsAI on June 29, 2026 to allow closing before a stockholder vote.
• Merger consideration totals 1,600,000,000 shares, split between common stock and new Series A Non-Voting Convertible Preferred Stock.
• InnocsAI holders receive common stock up to the Nasdaq issuance cap, estimated at 19.99% of pre-close shares outstanding.
• Each Series A preferred share converts into 10,000 common shares, subject to stockholder approval for the underlying issuance.
• Ancillary terms include registration rights for received shares, plus a two-year non-compete and non-solicitation pact for key employees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080613), on July 06, 2026, and is solely responsible for the information contained therein.